Half a Million Australians Using GLP-1 Drugs as Private Prescriptions Soar

Approximately 500,000 Australians are using GLP-1 receptor agonist medications for weight loss and diabetes management, according to data reported by Nine.com.au on July 31, 2026. The surge is driven largely by a rise in private prescriptions for drugs such as semaglutide and tirzepatide, which are used both for type 2 diabetes and chronic weight management.

Rising Private Prescription Rates for GLP-1 Drugs

The increase in GLP-1 use reflects a shift toward private healthcare spending to access these medications. While some versions of these drugs are subsidized by the government for specific medical indications, many users are paying out-of-pocket to obtain prescriptions for weight loss, according to Nine.com.au.

GLP-1 medications work by mimicking a hormone that targets areas of the brain that regulate appetite and food intake. This process slows gastric emptying, which helps patients feel full longer and reduces overall caloric intake.

Medical Applications and Weight Loss Trends

These medications were originally developed to treat type 2 diabetes by regulating blood sugar levels. However, their efficacy in inducing significant weight loss has led to widespread use as obesity treatments. The medications currently dominating the Australian market include semaglutide, marketed under brands like Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro and Zepbound.

The distinction between these brands often depends on whether they are approved specifically for diabetes or for chronic weight management. According to reporting from Nine.com.au, the volume of private prescriptions has soared as more individuals seek these treatments outside of the strict criteria required for government subsidies.

Public Health Implications and Access

The rapid adoption of GLP-1 drugs has raised concerns regarding medication supply and the long-term monitoring of patients. Because these drugs require ongoing administration and can have side effects—primarily gastrointestinal issues—health officials emphasize the necessity of medical supervision.

The high cost of private prescriptions creates a divide in access, where those with higher disposable income can access the drugs more readily than those relying on the Pharmaceutical Benefits Scheme (PBS). This trend highlights a growing reliance on private healthcare for metabolic health interventions in Australia.

Clinical Context of GLP-1 Agonists

Medical research indicates that GLP-1 agonists provide benefits beyond weight loss, including potential cardiovascular protections. However, clinical guidelines generally recommend these drugs as adjuncts to diet and exercise rather than standalone solutions.

The current trend in Australia follows a global pattern seen in the United States and Europe, where demand for these medications has occasionally outstripped supply, leading to shortages of the diabetes-specific versions of the drugs.